Our results identified that anti-leukemic effects of matrine were correlated with the inhibition of ERK/MAPK signaling activation and decreased expression of upstream BCR/ABL, which suggested that matrine might be of therapeutic utility in patients with CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.